scholarly journals Rare Gingival Metastasis by Hepatocellular Carcinoma

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Li-Jun Xue ◽  
Xiao-Bei Mao ◽  
Jian Geng ◽  
Ya-Nan Chen ◽  
Qian Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Histopathological Examination ◽  
Cerebral Metastases ◽  
Performance Score ◽  
Intravenous Chemotherapy ◽  
Pathological Characteristics ◽  
Gingival Metastasis ◽  
Sorafenib Therapy ◽  
Multiple Metastases ◽  
Poorly Differentiated

Hepatocellular carcinoma (HCC) uncommonly metastasizes to the gingiva, which always means a poor outcome. We reported a rare HCC case with multiple metastases to gingiva, lungs, and brain. A 60-year-old man was initially diagnosed as HCC with metastases to double lungs. He was subjected to a transarterial chemoembolization (TACE) (5-fluorouracil, 750 mg) and two cycles of intravenous chemotherapy (gemcitabine 1.8 g at days 1 and 8, oxaliplatin 200 mg at day 2, every 4 weeks). However, the volume of liver tumor still increased. A bean-size gingival nodule growing with occasional bleeding was also found. TACE (5-fluorouracil 750 mg, perarubicin 40 mg, cisplatin 20 mg) was performed again and an oral sorafenib therapy (400 mg, twice per day) was adopted. The disease maintained relatively stable for about 6 months until a second obvious progress. The gingival nodule was then palliatively excised and identified as a poorly differentiated metastatic HCC by histopathological examination. Best supportive treatments were made since the performance score was too bad. Finally, cerebral metastases occurred and the patient died of systemic failure. Upon review of previous reports, we discussed risk factors, clinical and pathological characteristics, treatments, and prognosis of gingival metastasis by HCC.

scholarly journals Isolated right ventricular metastasis of hepatocellular carcinoma induced by epithelial–mesenchymal transition: a case report

2020 ◽  
Author(s):  
Kosuke Saku ◽  
Nobuhiro Tahara ◽  
Yoshihiro Fukumoto ◽  
Hiroyuki Tanaka
Keyword(s):  
Hepatocellular Carcinoma ◽  
Right Ventricle ◽  
Right Ventricular ◽  
Epithelial Mesenchymal Transition ◽  
Histopathological Examination ◽  
Anticoagulation Therapy ◽  
Mesenchymal Transition ◽  
Poorly Differentiated ◽  
The Right ◽  
The Relationship

Abstract Background Hepatocellular carcinoma (HCC) that metastasizes to the right ventricle has rarely been reported. An important link between epithelial–mesenchymal transition (EMT) and the invasion and metastasis of cancer cells has recently been demonstrated. However, there are few reports on the relationship between HCC metastasized to the heart and EMT. Case summary We here report the case of a 74-year-old woman who had type C HCC referred to our hospital with general fatigue due to a right ventricular tumour diagnosed at a general hospital. Anticoagulation therapy was done, but the mass had rapidly grown. We performed surgical resection of the mass. Histopathological examination revealed that the tumour was diagnosed as a poorly differentiated HCC metastasis induced by EMT. Discussion Isolated metastasis of HCC to the right ventricle is extremely rare. The HCC with EMT has a potentially high risk of metastasizing to the heart and other organs, and the prognosis is poor.

scholarly journals Synchronous Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Case Report and Review of the Literature

2021 ◽  
Author(s):  
Meng-Meng Qu ◽  
Yuan-Hui Zhu ◽  
Yi-Xiang Li ◽  
Zhi-fan Li ◽  
Jin-Kui Li ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hepatic Resection ◽  
Intrahepatic Cholangiocarcinoma ◽  
Histopathological Examination ◽  
Primary Hepatocellular Carcinoma ◽  
Pathological Examination ◽  
B Virus ◽  
Poorly Differentiated

Abstract Background: Synchronous double primary hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) (sdpHCC-ICC) located separately within a single liver is extremely rare. The purpose of this study is to investigate the clinical, imaging, pathological characteristics and prognosis of patients with sdpHCC-ICC, in order to enhance our understanding of the disease and improve diagnostic and therapeutic effect.Case presentation: A 49-year-old female patient with obvious liver cirrhosis, who carried hepatitis B virus, was admitted to our hospital for physical examination. The level of α-fetoprotein (AFP) and carbohydrate antigen 19-9 (CA19-9) was found to be elevated. Abdominal ultrasonography and enhanced computed tomography revealed two solid masses located in segments (S) 4 and 6 of the liver, with malignant behaviors. The preoperation diagnosis was multiple primary hepatocellular carcinomas. We performed hepatic resection of both segments. The resected specimens revealed that the tumors in segments 4 and 6 were well-defined lesions of 5.0 cm and 2.5cm, respectively. Histopathological examination confirmed that the tumor of the 4th segment to be moderately and poorly differentiated ICC, and that the tumor of the 6th segment to be poorly differentiated HCC. Immunohistochemically, the ICC in S4 was positive for CK19 and negative for Heppar-1, while the HCC in S6 was positive for Heppar-1 and negative for CK19. Unfortunately，metastasis and recurrence of multiple organs and lymph nodes were observed only 3 months later.Conclusions: The clinical characteristics of sdpHCC-ICC are usually atypical. It is of difficulty to make an accurate preoperative diagnosis. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection were both the independent risk factor to the development of sdpHCC-ICC. In patients with chronic liver disease, careful observation with imaging examination should be necessary. Tumor markers may be valuable to the diagnosis of it. The definite diagnosis depends on pathological examination. Hepatic resection may be the preferred and most effective treatment. The prognosis of synchronous occurrence of double hepatic cancers was poorer than for either HCC or ICC, and the origin of it needs further study.

Sinusoidal endothelial cell progenitor cells promote tumor progression in the patients with hepatocellular carcinoma.

2020 ◽  
Author(s):  
Ya-xing Feng ◽  
Wei Li ◽  
Xu-dong Wen ◽  
Ning Zhang ◽  
Zhan-yu Yang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Endothelial Cell ◽  
Tumor Progression ◽  
Progenitor Cells ◽  
Tumor Markers ◽  
Liver Tumors ◽  
Sinusoidal Endothelial Cell ◽  
Double Staining ◽  
Pathological Characteristics ◽  
Poorly Differentiated

Abstract Objective: Since sinusoidal endothelial cell progenitor cells (SEPCs) play great roles in liver regeneration, it is necessary to elucidate that whether these SEPCs participate in tumor progression of hepatocellular carcinoma (HCC).Methods: A total of 45 patients with primary HCC, who received liver resection, were included in this study. The liver tumors were removed from patients and partial tissues were prepared to identify SEPCs by double staining of CD133/CD45 and CD133/CD31 at the same location. Blood samples were correspondingly collected to examine liver function parameters and tumor markers. The demographics and clinic-pathological characteristics of the patients were all collected for correlation analysis with SEPCs.Results: SEPCs were observed within abundant of blood vessels in HCC nodules of all the 45 patients, but no SEPCs were detected in the tumor-adjacent tissues. The number of SEPCs was correlated with the expression levels of HCC tumor markers α-fetoprotein (AFP) and CA199. There was a positive correlation between the expressions of SEPCs markers and the diameters of HCC tumors in differently differentiated specimens (P<0.01). The expressions levels of SEPCs markers in poorly differentiated HCC patients were significantly higher than those in the moderately and highly differentiated HCC patients (P<0.05).Conclusions: SEPCs are in close connection with HCC progression, and they may potentially act as prognosis and metastasis predicting index and even therapeutic candidates of HCC.

scholarly journals Immunohistochemical detection of procalcitonin in fibrolamellar hepatocellular carcinoma

2021 ◽  
Author(s):  
Kotaro Matsumoto ◽  
Kentaro Kikuchi ◽  
Ayako Hara ◽  
Hiromichi Tsunashima ◽  
Koichi Tsuneyama ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Histopathological Examination ◽  
Epigastric Pain ◽  
Positive Staining ◽  
C Reactive Protein ◽  
Fibrolamellar Hepatocellular Carcinoma ◽  
Tumor Biopsy ◽  
Reactive Protein ◽  
Right Lobe ◽  
The Right

AbstractA 25-year-old woman with fever and epigastric pain was referred to our hospital. Blood examination showed significant liver dysfunction, markedly high C-reactive protein (CRP 19.1 mg/dL) and procalcitonin (48.3 ng/mL) levels. Dynamic computed tomography showed a tumor approximately 120 mm in size in the right lobe of the liver, but with no abscess formation. The patient was hospitalized and started on antibiotics; her CRP level improved, but the procalcitonin level did not decrease. Histopathological examination of the liver tumor biopsy revealed fibrolamellar hepatocellular carcinoma (FLC). Positive staining of the FLC with an anti-procalcitonin antibody suggested the production of procalcitonin.

scholarly journals Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series

2021 ◽  
pp. 224-231
Author(s):  
Richard T. Lee ◽  
Peiying Yang ◽  
Asrar Alahmadi ◽  
Jennifer McQuade ◽  
Eric Yuan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Time ◽  
Injection Site Reaction ◽  
Case Series ◽  
Advanced Hepatocellular Carcinoma ◽  
Site Reaction ◽  
Advanced Hcc ◽  
Mistletoe Extract ◽  
Sorafenib Therapy ◽  
Mistletoe Extracts

Background: Hepatocellular carcinoma (HCC) is the fourth leading cause of death from cancer worldwide, and for advanced HCC the prognosis is poor. Preliminary studies indicate mistletoe extracts may have anticancer activity for HCC. Methods: A prospective observational case series of advanced HCC patients that chose to take a mistletoe extract called viscum fraxini-2 (VF-2) alone for treatment. Time on treatment, imaging, and laboratory values were collected for descriptive analyses. Results: A total of 12 patients with advanced HCC enrolled onto the protocol, and 10 patients had data available for evaluation. The majority were male (10/12) with a median age of 64 (SD 11). Most patients had received sorafenib therapy (9/12) and had varying Child-Pugh classes (A-4, B-6, C-2). Treatment with VF-2 ranged from 1 to 36 weeks with a mean of 12.3 weeks (SD 12). Six patients received 8 weeks of treatment, and 3 patients received 12 or more weeks of treatment. For patients that received at least 4 weeks of treatment, the average AFP value stabilized during the first 4 weeks of treatment. Two patients experienced an AFP decrease of >30%, approximately 37 and 40% decreases at the nadir. One patient had stable disease of 9 months. Major side effects were fever, fatigue, rash, and local injection site reaction of swelling, redness, and tenderness. Conclusion: This case series of advanced HCC indicates that mistletoe extract VF-2 may have potential biological activity against HCC for selected patients. Research is needed to identify the active compound and predictive markers of response.

684 MODERATELY DIFFERENTIATED ESOPHAGEAL SQUAMOUS CELL CARCINOMA HAS A POOR PROGNOSIS AFTER NEOADJUVANT CHEMORADIOTHERAPY

2021 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
Xue-feng Leng ◽  
Tianqin Mao ◽  
Jiaxin Yan ◽  
Xuefeng Leng ◽  
Yongtao Han
Keyword(s):  
Squamous Cell Carcinoma ◽  
Lymph Node ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Neoadjuvant Chemoradiotherapy ◽  
Residual Tumor ◽  
Lymph Node Status ◽  
Pathological Characteristics ◽  
Poorly Differentiated

Abstract   Neoadjuvant chemoradiotherapy (NCRT) plus surgery is the standard treatment for esophageal squamous cell carcinoma (ESCC); however, further analysis is needed to detail the histopathological characteristics of ESCC and their clinical significance after NCRT. This study aimed to present the pathological characteristics of ESCC and their association with prognosis after NCRT. Methods All patients with ESCC who underwent NCRT followed by surgical resection at Sichuan Cancer Hospital (China) from January 2018 to December 2019 were included. Resection specimens of both the primary disease and lymph nodes were re-evaluated by an experienced pathologist. After NCRT, the pathological characteristics of the residual tumor were evaluated based on the Japanese residual tumor pattern, Mandard tumor regression grade (Mandard-TRG), local inflammatory infiltration classification, and lymph node status. Results Among the 103 patients with ESCC included in this study, the pathological complete response (pCR) rate was 34% (35/103). The pCR rate of patients with poorly differentiated tumors (31/72) was higher (43.1%) than that of patients with well or moderately differentiated tumors (P &lt; 0.05). The residual tumor rate was 66% (68/103). A positive correlation was noted between the Japanese residual tumor pattern and Mandard-TRG (Kendall’s tau-b = 0.857, P &lt; 0.001). Tumor infiltration depth, lymph node positivity, moderate differentiation, and tumor recurrence were associated with poor oncological outcomes (P &lt; 0.05). Conclusion Patients with poorly differentiated tumors can obtain an excellent short-term response; however, they have extremely poor long-term survival. For patients with moderately differentiated tumors, both the short- and long-term outcomes are poor. Lymph node status after NCRT is a prognostic factor for ESCC treated with NCRT.

scholarly journals PAPILLARY CARCINOMA, A METASTASIS OF THE BRAIN AND BONE: A RARE CASE

2020 ◽  
Vol 73 (10) ◽  
pp. 2306-2308
Author(s):  
Volodymyr B. Dobrorodniy ◽  
Anatoliy D. Bedenyuk ◽  
Viktoria G. Khoperiia ◽  
Andriy V. Dobrorodniy
Keyword(s):  
Papillary Carcinoma ◽  
Rare Case ◽  
Cerebral Metastases ◽  
Papillary Thyroid ◽  
Rare Presentation ◽  
Large Size ◽  
Multiple Metastases ◽  
Uncommon Condition ◽  
Metastatic Sites ◽  
The Brain

Cerebral metastases from papillary carcinoma of the thyroid are a very uncommon condition. These metastases almost always involve concomitant lung or bone metastases which may be the first metastatic sites. In a 59-year-old woman found metastases of papillary thyroid cancer (PTC) in the frontal sinus, scapula, multiple bones of the skeleton and lungs. Evaluation confirmed that it is multiple metastases from PTC. This is a very rare presentation with such a large size of metastasis. We present this rare clinical case of massive distal lesions in PTC.

scholarly journals Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan

2014 ◽  
Vol 5 (7) ◽  
pp. 499-509 ◽  
Author(s):  
Hiroki Nishikawa ◽  
Haruhiko Takeda ◽  
Kaoru Tsuchiya ◽  
Kouji Joko ◽  
Chikara Ogawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Outcome ◽  
Multicenter Study ◽  
Aged Patients ◽  
Sorafenib Therapy

scholarly journals Prediction of poorly differentiated hepatocellular carcinoma using contrast computed tomography

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Kenichiro Nakachi ◽  
Hideyuki Tamai ◽  
Yoshiyuki Mori ◽  
Naoki Shingaki ◽  
Kosaku Moribata ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Hepatocellular Carcinoma ◽  
Poorly Differentiated

scholarly journals Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab

2019 ◽  
Vol 12 (9) ◽  
pp. e228917 ◽  
Author(s):  
Karla A Lee ◽  
Margherita Cioni ◽  
Alistair Robson ◽  
Veronique Bataille
Keyword(s):  
Squamous Cell Carcinoma ◽  
Brain Metastases ◽  
Cell Carcinoma ◽  
Clinical Response ◽  
Lower Limb ◽  
Histopathological Examination ◽  
Nodal Metastases ◽  
Left Lower Limb ◽  
Poorly Differentiated ◽  
Visceral Disease

A 67-year-old woman presented in 2012 with a crusty nodule on the left lower limb. Histopathological examination at this time reported a poorly differentiated squamous cell carcinoma (SCC). Two years later, she underwent lymphadenectomy and radiotherapy due to unilateral inguinal and pelvic sidewall nodal metastases. The following year she required excision of two subcutaneous lesions, reported pathologically to be SCC metastases. Further imaging following cyberknife radiotherapy to new brain metastases demonstrated widespread metastatic visceral disease. Twelve cycles of carboplatin and capecitabine failed to halt disease progression. In February 2017, she commenced pembrolizumab, achieving an excellent response and currently has no clinical or radiological evidence of disease. Given the unusual behaviour of her cancer, a histopathological review was requested. The diagnosis was revised to that of porocarcinoma (PC). This represents the first documented case of PC treated with immunotherapy. As of March 2019, the patient remains free of disease.

Sign in / Sign up

Export Citation Format

Share Document